FDA Delays Exelixis' Zanzalintinib Review: What It Means for Investors
The FDA's delay in reviewing Exelixis' zanzalintinib raises questions for investors about future revenue and growth.
Exelixis Faces Setback as FDA Extends Review of Zanzalintinib
Exelixis faces uncertainty as the FDA prolongs its review of zanzalintinib, raising questions about future revenue and stock performance.
Merck and Moderna's mRNA Breakthrough: Implications for the Future of Cancer Treatment
The Phase 3 INTerpath-001 trial results present significant implications for Merck and Moderna's cancer treatment strategies.
Quantum BioPharma's FDA Clearance: A Game Changer for MS Treatment
Quantum BioPharma's FDA clearance for Lucid-MS could reshape MS treatment and enhance investor confidence.
Merck (MRK) and Moderna (MRNA) Achieve Breakthrough in mRNA Cancer Vaccine Development: What it Means for Investors
Merck and Moderna's Phase 3 trial results for their mRNA cancer vaccine could reshape oncology and investor sentiment.
Revolution Medicines (RVMD) Gains Momentum Post-FDA Approval: What Investors Should Know
Revolution Medicines is gaining traction following FDA approval for Rasonque, signaling potential market shifts.
Revolution Medicines Gains Traction with FDA Approval of Rasonque and Morgan Stanley Overweight Rating
Revolution Medicines sees renewed investor interest as Rasonque gains FDA approval and Morgan Stanley issues an Overweight rating.
Genentech's Enspryng Gets FDA Priority Review for MOGAD: What the Accelerated Timeline Means
The FDA's Priority Review of Enspryng for rare disease MOGAD could compress Genentech's approval timeline and unlock a new patient segment i…
Axogen Expands Nerve Repair Portfolio with $200M BioCircuit Acquisition
Axogen's $200M acquisition of BioCircuit Technologies marks a significant expansion in the nerve repair market.
Roivant Sciences Gains Traction as Mosliciguat Progresses to Phase 3 Trials
Roivant Sciences sees increased investor confidence as it advances mosliciguat to Phase 3 trials, boosted by TD Cowen's price target raise.
Intellia's Groundbreaking CRISPR Therapy Receives FDA Priority Review
Intellia's lonvoguran ziclumeran receives FDA Priority Review, positioning NTLA as a leader in CRISPR gene editing.
Merck and Moderna's Game-Changing Melanoma Vaccine Trial Success
A pivotal Phase 3 trial success could reshape the oncology landscape for melanoma treatment, presenting significant investor implications.